Minneapolis Heart Institute Foundation researcher to present at Young Investigators' Forum

November 07, 2014

Minneapolis, MN - November 7, 2014 - Dr. Ankur Kalra, MD, the chief cardiovascular fellow at the Minneapolis Heart Institute, will present today at the Tenth Annual Cardiovascular Young Investigators' Forum behind held in Chicago, Illinois on November 6-9, 2014. Dr. Kalra's presentation, titled "Doppler Tissue Imaging Predicts Progressive Heart Failure Prognosis in Hypertrophic Cardiomyopathy," is the product of a study conducted using the Minneapolis Heart Institute Foundation's extensive Hypertrophic Cardiomyopathy (HCM) database, which was compiled in large part by MHIF Research Cardiologist Dr. Barry Maron.

Until Dr. Kalra began his study, limited research had been conducted on the causes of heart failure progression in HCM patients. Researchers had investigated the risk factors of sudden cardiac death due to HCM, but the risk factors in HCM patients that are associated with heart failure progression remained unstudied and unknown. Previously, family history was the only risk factor associated with heart failure progression in HCM, a conclusion derived from a study conducted by MHIF Research Cardiologist Dr. Kevin M. Harris. Now, Dr. Kalra has made significant headway in identifying a risk marker in HCM patients that is associated with heart failure progression.

In the study, Dr. Kalra examined echocardiograms of 404 patients, looking at Doppler tissue imaging (DTI) to determine whether it has an association with heart failure progression in HCM. He found that the existence of abnormalities in DTI on initial echocardiogram is an independent risk marker for progression to HCM-related heart failure death, cardiac transplantation or progression of heart failure symptoms. Being able to identify a high risk of heart failure progression then allows for aggressive management and closer monitoring of high-risk patients.

Forty presentations in two categories - clinical and basic science - will be heard at the Young Investigators' Forum. Dr. Kalra's presentation will be made in the clinical category. One person in each category will receive $10,000 to conduct further research. The Forum is an independent medical education activity accredited by Northwestern University Feinberg School of Medicine, Office of Continuing Medical Education.
-end-
About the Minneapolis Heart Institute Foundation

The Minneapolis Heart Institute Foundation is dedicated to creating a world without heart disease through groundbreaking clinical and population health research and community outreach. MHIF's mission is to improve people's lives through the highest quality cardiovascular research and education.

Scientific Innovation and Research - Publishing more than 120 peer-reviewed studies each year, MHIF is a recognized research leader in the broadest range of cardiovascular medicine. Each year, cardiologists and hospitals around the world adopt MHIF protocols to save lives and improve patient care.

Education and Outreach - Research shows that modifying specific health behaviors can significantly reduce the risk of developing cardiovascular disease. As part of its mission, the Minneapolis Heart Institute Foundation has been involved in cutting-edge, transformative population health research to connect, engage, inform and empower individuals and communities to improve their health.

About the Minneapolis Heart Institute®

The Minneapolis Heart Institute® is recognized internationally as one of the world's leading providers of heart and vascular care. This state-of-the-art facility combines the finest in personalized patient care with sophisticated technology in a unique, family-oriented environment. The Institute's programs, a number of which are conducted in conjunction with Abbott Northwestern Hospital, address the full range of heart and vascular health needs: prevention, diagnosis, treatment and rehabilitation.

Minneapolis Heart Institute Foundation

Related Hypertrophic Cardiomyopathy Articles from Brightsurf:

New medication may treat underlying causes of hypertrophic cardiomyopathy
Mavacamten, a new investigational cardiac medication, may improve heart function for people with thickened heart muscle leading to obstructed blood flow through the heart, a condition known as obstructive hypertrophic cardiomyopathy.

Study reinforces drug's potential to treat hypertrophic cardiomyopathy
WSU research sheds new light on a molecule that may be used to treat heart conditions that can lead to stroke, heart attack and other forms of heart disease.

Shared protein fingerprint could simplify treatment of common inherited heart disease
University of Wisconsin-Madison scientists discovered that many different genetic mutations result in surprisingly similar changes to heart muscle proteins in patients with the most severe manifestations of hypertrophic cardiomyopathy.

Trial supports first specific treatment for obstructive hypertrophic cardiomyopathy
Mavacamten improves heart function and symptoms in patients with obstructive hypertrophic cardiomyopathy, according to results of the EXPLORER-HCM trial presented in a Hot Line session today at ESC Congress 2020.

Comparing stress cardiomyopathy before, during COVID-19 pandemic
Patients with acute coronary syndrome presenting during the COVID-19 pandemic were compared with patients presenting at times prior to the pandemic to investigate the incidence of stress cardiomyopathy during the pandemic in this observational study.

Connecting the dots between heart disease, potential for worse COVID-19 outcomes
People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown.

Mayo researchers create, test AI to improve EKG testing for hypertrophic cardiomyopathy
An approach based on artificial intelligence (AI) may allow EKGs to be used to screen for hypertrophic cardiomyopathy in the future.

New gene mutation associated with Fabry cardiomyopathy
The A143T variant of the GLA gene is associated with an increased risk of Fabry cardiomyopathy, according to a new study.

Tracking a silent killer: New biomarker identified for arrhythmogenic cardiomyopathy
Scientists have identified a metabolic biomarker that could help track the progression of arrhythmogenic cardiomyopathy (AC) -- an inherited heart condition that can kill swiftly and without warning -- in a study of heart tissue and plasma from patients with AC.

How race is associated with differences among patients with hypertrophic cardiomyopathy
Researchers in this observational study looked at how race was associated with difference in symptoms, access to care, genetic testing and clinical outcomes among 2,467 patients (8.3% black and 91.7% white) with hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick, which can make it harder to pump blood.

Read More: Hypertrophic Cardiomyopathy News and Hypertrophic Cardiomyopathy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.